Pfizer Inc. $PFE Stock Acquired by Wedmont Private Capital

Key Points

• Wedmont Private Capital increased its Pfizer stake by 138.1% in the third quarter, bringing its holdings to 99,498 shares valued at approximately $2.77 million. Institutional investors and hedge funds collectively own 68.36% of Pfizer.
• Analyst sentiment remains broadly neutral: five analysts rate Pfizer a Buy, 14 rate it a Hold and two rate it a Sell, with an average price target of $28.72.
• Pfizer reported quarterly earnings and revenue above expectations and guided to fiscal 2026 earnings of $2.80–$3.00 per share. The company announced a quarterly dividend of $0.43 per share, equivalent to a 6.1% annualized yield, though its payout ratio exceeds 200%.

Wedmont Private Capital raised its position in shares of Pfizer Inc. (NYSE:PFE - Free Report) by 138.1% in the 3rd quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 99,498 shares of the biopharmaceutical company's stock after purchasing an additional 57,713 shares during the period. Wedmont Private Capital's holdings in Pfizer were worth $2,768,000 at the end of the most recent reporting period.

A number of other large investors have also recently modified their holdings of the business. Retirement Wealth Solutions LLC increased its stake in shares of Pfizer by 144.6% in the 3rd quarter. Retirement Wealth Solutions LLC now owns 861 shares of the biopharmaceutical company's stock valued at $25,000 after purchasing an additional 509 shares during the last quarter. Evolution Wealth Management Inc. lifted its position in shares of Pfizer by 132.2% during the 1st quarter. Evolution Wealth Management Inc. now owns 994 shares of the biopharmaceutical company's stock worth $28,000 after buying an additional 566 shares during the last quarter. Keb Asset Management LLC acquired a new stake in Pfizer in the second quarter valued at about $26,000. Field & Main Bank bought a new position in Pfizer in the second quarter valued at about $27,000. Finally, Global Trust Asset Management LLC grew its position in Pfizer by 126.7% in the first quarter. Global Trust Asset Management LLC now owns 1,163 shares of the biopharmaceutical company's stock valued at $33,000 after acquiring an additional 650 shares during the last quarter. Institutional investors and hedge funds own 68.36% of the company's stock.

Analyst Ratings Changes

A number of research analysts have recently commented on PFE shares. Scotiabank increased their target price on shares of Pfizer from $30.00 to $33.00 and gave the stock an "outperform" rating in a report on Tuesday. Guggenheim decreased their price target on shares of Pfizer from $35.00 to $31.00 and set a "buy" rating on the stock in a report on Friday, August 7th. HSBC upped their price objective on shares of Pfizer from $28.00 to $30.00 and gave the stock a "hold" rating in a research report on Thursday, September 10th. Bank of America dropped their price objective on shares of Pfizer from $27.00 to $26.00 and set a "neutral" rating for the company in a research note on Friday, July 10th. Finally, JPMorgan Chase & Co. raised their target price on shares of Pfizer from $28.00 to $30.00 and gave the company a "neutral" rating in a research report on Friday. Five investment analysts have rated the stock with a Buy rating, fourteen have given a Hold rating and two have given a Sell rating to the company's stock. Based on data from MarketBeat.com, the company has an average rating of "Hold" and an average price target of $28.72.

Pfizer News Summary

Here are the key news stories impacting Pfizer this week:

• Positive Sentiment: Analyst support improved: JPMorgan raised its price target from $28 to $30 while maintaining a neutral rating, and Jefferies issued a buy rating. Cantor Fitzgerald also increased its target to $28, signaling some potential downside protection at current levels.
• Positive Sentiment: TUKYSA approval expands Pfizer’s oncology opportunity: The FDA approved TUKYSA in combination with trastuzumab and pertuzumab as a chemotherapy-free frontline maintenance treatment for certain patients with HER2-positive metastatic breast cancer. Moving the drug into an earlier line of treatment could broaden its commercial reach. FDA Backs Pfizer’s TUKYSA Combination
• Positive Sentiment: Pipeline progress adds longer-term support: Pfizer’s Phase 3 trial of tilrekimig, an asthma candidate, is advancing. Investors are also focused on oncology sales, biosimilars and the late-stage pipeline ahead of quarterly results. Tilrekimig Phase 3 Trial Update
• Positive Sentiment: Income and valuation appeal remain catalysts: Pfizer’s dividend announcement, roughly 6% yield and valuation below many large pharmaceutical peers continue to attract income and value-oriented investors. The company also has a history of earnings beats, with its latest reported quarter exceeding consensus estimates for both earnings and revenue.
• Neutral Sentiment: Investor attention is elevated: Pfizer was among heavily searched stocks, while broader biotechnology interest was helped by Moderna’s Nasdaq-100 inclusion. These factors may increase trading activity but do not directly change Pfizer’s fundamentals.
• Negative Sentiment: High yield raises risk concerns: Commentary warns that Pfizer’s unusually large dividend yield may reflect investor doubts about earnings, cash flow, debt and the durability of the payout. Sluggish revenue growth, a thin net margin and relatively low return on equity reinforce those concerns. Pfizer Dividend Yield Analysis
• Negative Sentiment: Cost-cutting highlights operational pressure: Pfizer plans to close a penicillin unit in Italy and eliminate about 330 jobs, underscoring efforts to improve efficiency amid a challenging growth outlook. Pfizer Italy Penicillin Unit Closure

Pfizer Price Performance

Pfizer stock opened at $28.27 on Friday. The stock has a 50-day moving average price of $27.68 and a two-hundred day moving average price of $26.50. Pfizer Inc. has a 12 month low of $23.62 and a 12 month high of $29.21. The company has a market capitalization of $161.14 billion, a PE ratio of 37.20, a P/E/G ratio of 1.87 and a beta of 0.32. The company has a current ratio of 1.27, a quick ratio of 0.96 and a debt-to-equity ratio of 0.71.

Pfizer (NYSE:PFE - Get Free Report) last released its quarterly earnings results on Tuesday, August 4th. The biopharmaceutical company reported $0.77 earnings per share for the quarter, topping the consensus estimate of $0.68 by $0.09. Pfizer had a return on equity of 19.63% and a net margin of 6.80%. The company had revenue of $15.03 billion for the quarter, compared to analysts' expectations of $14.40 billion. During the same period in the previous year, the business posted $0.78 earnings per share. The business's quarterly revenue was up 2.6% compared to the same quarter last year. Pfizer has set its FY 2026 guidance at 2.800-3.000 EPS. Analysts expect that Pfizer Inc. will post 2.98 EPS for the current year.

Pfizer Announces Dividend

The firm also recently announced a quarterly dividend, which will be paid on Monday, December 7th. Shareholders of record on Friday, November 6th will be issued a dividend of $0.43 per share. This represents a $1.72 dividend on an annualized basis and a yield of 6.1%. The ex-dividend date of this dividend is Friday, November 6th. Pfizer's payout ratio is presently 226.32%.

About Pfizer

Pfizer Inc NYSE: PFE is a global biopharmaceutical company that discovers, develops, manufactures and commercializes prescription medicines and vaccines. Its research and commercial activities focus on areas including oncology, inflammation and immunology, internal medicine, hospital care and vaccines.

The company's portfolio includes widely used products such as the Prevnar family of pneumococcal vaccines, Ibrance for certain breast cancers, Eliquis for preventing blood clots, Xeljanz for inflammatory conditions, and Vyndaqel for transthyretin amyloidosis.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.